DIFLORASONE DIACETATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DIFLORASONE DIACETATE (DIFLORASONE DIACETATE).
Diflorasone diacetate is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions. It induces phospholipase A2 inhibitory proteins (lipocortins), thereby controlling the biosynthesis of potent mediators of inflammation like prostaglandins and leukotrienes.
| Metabolism | Topical corticosteroids are metabolized primarily in the liver via reduction, oxidation, and conjugation pathways. Specific enzymes for diflorasone diacetate are not well characterized. |
| Excretion | Primarily renal (≤5% unchanged); extensive hepatic metabolism with biliary/fecal elimination of metabolites; total recovery: ~60% in urine (metabolites), ~30% in feces. |
| Half-life | Terminal elimination half-life of approximately 5.7 hours (range 4.4–7.1 h) after topical application; prolonged in hepatic impairment. |
| Protein binding | ~90% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | Not well characterized for topical route; systemic Vd after IV administration in animal models is approximately 1–2 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Topical: Systemic bioavailability is low (<1%) when applied to intact skin; may increase to 2–10% on abraded or inflamed skin; occlusive dressings enhance absorption. |
| Onset of Action | Topical: Noticeable relief of pruritus and inflammation within 12–24 hours; maximal effect typically within 1–2 weeks of regular application. |
| Duration of Action | Topical: Therapeutic effect persists for 24 hours after a single application; sustained use recommended for up to 2 weeks for full benefit. |
| Molecular Weight | 447.53 |
Apply a thin film to affected skin areas twice daily (every 12 hours). Use the lowest effective strength and duration.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment; systemic absorption is minimal with topical use. |
| Liver impairment | No dosage adjustment required for hepatic impairment; minimal systemic absorption. |
| Pediatric use | Use lowest potency and shortest duration; avoid use in infants under 1 year. For children 1-12 years, apply a thin film once or twice daily, limit to small areas. Safety and efficacy not fully established. |
| Geriatric use | Use with caution due to thinner skin and increased risk of skin atrophy; apply smallest amount for shortest duration necessary. |
| 1st trimester | Data limited. Topical corticosteroids should be used in pregnancy only if potential benefit justifies risk. Avoid use in large amounts or for prolonged periods. |
| 2nd trimester | Same as t1. No specific data indicating harm, but caution advised. |
| 3rd trimester | Same as t1. Prolonged use may cause fetal growth restriction or adrenal suppression. |
Clinical note
Comprehensive clinical and safety monograph for DIFLORASONE DIACETATE (DIFLORASONE DIACETATE).
| Placental transfer | Topical corticosteroids can be absorbed sufficiently to produce systemic effects, and placental transfer occurs. The extent is dose-dependent and increased with occlusive dressings or large surface area application. |
| Breastfeeding | Systemic absorption after topical application is minimal; however, apply to smallest area possible and avoid application to breast or nipple area. No data on excretion in breast milk. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to diflorasone diacetate or any component of the formulationViral or fungal infections of the skinRosaceaPerioral dermatitis
| Precautions | Systemic absorption may lead to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria., Pediatric patients may be more susceptible to systemic toxicity due to larger skin surface-to-body weight ratio., Prolonged use, use on large areas, occlusive dressing, or on broken skin increases systemic absorption., Local adverse reactions include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, and miliaria. |
| Food/Dietary | No clinically significant food interactions. No dietary restrictions necessary. |
Loading safety data…
| Lactation Rating | L3: Limited Data - Probably Compatible |
| Teratogenic Risk | Topical corticosteroids are generally considered low risk for teratogenicity when used appropriately. Diflorasone diacetate is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects with topical corticosteroids, but there are no adequate human studies. Systemic absorption is minimal with topical application, but risk cannot be excluded. First trimester: theoretical risk; second and third trimesters: low risk with short-term use on limited areas. Avoid prolonged use or application to large areas. |
| Fetal Monitoring | Monitor for maternal signs of HPA axis suppression (e.g., weight gain, hyperglycemia, hypertension) if used extensively. Fetal monitoring not routinely required unless high-dose or prolonged use; consider ultrasound for growth assessment with chronic use. |
| Fertility Effects | No known effects on fertility in humans. Animal studies have not reported reproductive impairment. High-dose systemic corticosteroids may affect fertility, but topical application unlikely. |
| Clinical Pearls | Diflorasone diacetate is a high-potency topical corticosteroid. Avoid use on the face, groin, axillae, or intertriginous areas due to increased risk of atrophy and systemic absorption. Limit treatment duration to 2 weeks; use no more than 45-50 g/week in adults to minimize HPA axis suppression. Occlusive dressings potentiate penetration but increase risk of adverse effects; use only under strict supervision for recalcitrant lesions. |
| Patient Advice | Apply a thin layer to affected skin only; do not use on healthy skin. · Wash hands after application unless treating hands. · Do not cover treated area with bandages or wraps unless directed by your doctor. · Avoid contact with eyes, mouth, or open wounds. · Do not use for longer than prescribed; prolonged use can cause skin thinning and systemic side effects. · Inform your doctor if you experience worsening rash, skin infection, or signs of adrenal suppression (e.g., fatigue, dizziness). |